Norwegian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
artesunate/fever
Koblingen er lagret på utklippstavlen
Side 1 fra 319 resultater
Blackwater fever in a non-immune patient with Plasmodium falciparum malaria after intravenous artesunate.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
Blackwater fever was typically reported after quinine administration, although it is poor recognized in patients receiving artesunate. This case describes a blackwater fever in a non-immune patient after artesunate for severe malaria. It highlights the importance of monitoring haemolytic parameters
Artesunate-related fever and delayed hemolysis in a returning traveler.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
Malaria is a serious and sometimes fatal disease caused by an intraerythrocytic parasite, and is commonly seen in developing countries. Approximately 1500 cases of malaria are diagnosed in the United States each year, mostly in travelers and immigrants returning from endemic areas [1]. There are
A randomized, comparative study of supervised and unsupervised artesunate-amodiaquine, for the treatment of uncomplicated malaria in Ghana.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
Although the use of artesunate-amodiaquine treatment is growing in Africa, data on its effectiveness are limited. In only the second published comparison of supervised and unsupervised treatments with this combination, Ghanaian children with uncomplicated malaria have recently been investigated in
Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND
Artesunate and amodiaquine (AS&AQ) is at present the world's second most widely used artemisinin-based combination therapy (ACT). It was necessary to evaluate the efficacy of ACT, recently adopted by the World Health Organization (WHO) and deployed over 80 countries, in order to make an
Efficacy of Artesunate/Amodiaquine in the Treatment of Uncomplicated Malaria among Children in Ghana.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
The declining efficacy of chloroquine in the early 2000s in Ghana led to its replacement with artesunate/amodiaquine (AS/AQ) combination as first-line drug for treating uncomplicated malaria in 2005. Since then efficacy studies have been ongoing in the country to provide continuous data on the
Comparative study of efficacy of artesunate plus cotrimoxazole and artesunate plus chloroquine in the treatment of malaria in Nigerian children: a preliminary report.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
OBJECTIVE
The study was undertaken to evaluate the efficacy of cotrimoxazole plus artesunate and to compare the efficacy of this combination with that of artesunate plus chloroquine in the treatment of acute uncomplicated falciparum malaria in children.
METHODS
Children aged between 0.5 and 12 yr
Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
The clinical efficacy of oral and intravenous (iv) artesunate was compared in an open randomized trial in 50 male adult patients with uncomplicated Plasmodium falciparum malaria in Kibaha, Tanzania. Oral artesunate treatment was started with 2 x 50 mg initially followed by 50 mg 12 hr later and then
Oral artesunate for neonatal malaria.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
A 24-day male baby presented with a history of fever and poor feeding. The baby was pale and had hepatosplenomegaly. Peripheral blood films revealed Plasmodium vivax. Chloroquine is the drug of choice in neonatal malaria. However, our patient did not respond to chloroquine. There has been very
Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
The standard adult treatment regimen for Plasmodium vivax malaria is chloroquine (1500 mg over 3 d) plus primaquine (15 or 30 mg daily for 14 d), but patient compliance tends to be poor with the lengthy course. Preliminary observations are reported on the efficacy of a shorter treatment course -
Artemisia annua and Artemisia afra tea infusions vs. artesunate-amodiaquine (ASAQ) in treating Plasmodium falciparum malaria in a large scale, double blind, randomized clinical trial.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND
Despite evidence from developing world trials that intravenous (IV) artesunate (AS) is superior to IV quinine (Q) in severe falciparum malaria (FM), IV AS remains unlicensed in the UK with national guidelines listing it as an acceptable alternative to IV Q as the drug of choice. We
Severe delayed autoimmune haemolytic anaemia following artesunate administration in severe malaria: a case report.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND
Parenteral artesunate is recommended as first-line therapy for severe and complicated malaria. Although its efficacy has been proven, long-term safety profile is still under evaluation. Several cases of delayed haemolytic anaemia occurred after initial clinical improvement and resolution
Efficacy of artesunate-amodiaquine for the treatment of acute uncomplicated falciparum malaria in southern Mauritania.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND
A regular evaluation of therapeutic efficacy in sentinel sites and a system of surveillance are required to establish treatment guidelines and adapt national anti-malarial drug policy to the rapidly changing epidemiology of drug-resistant malaria. The current anti-malarial treatment
Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND
Children are most vulnerable to malaria. A pyronaridine-artesunate pediatric granule formulation is being developed for the treatment of uncomplicated Plasmodium falciparum malaria.
METHODS
This phase III, multi-center, comparative, open-label, parallel-group, controlled clinical trial
Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial.
Bare registrerte brukere kan oversette artikler
Logg inn Registrer deg
BACKGROUND
Sparse data on the safety of pyronaridine-artesunate after repeated treatment of malaria episodes restrict its clinical use. We therefore compared the safety of pyronaridine-artesunate after treatment of the first episode of malaria versus re-treatment in a substudy analysis.
METHODS
This
Den mest komplette databasen med medisinske urter støttet av vitenskap
- Fungerer på 55 språk
- Urtekurer støttet av vitenskap
- Urtegjenkjenning etter bilde
- Interaktivt GPS-kart - merk urter på stedet (kommer snart)
- Les vitenskapelige publikasjoner relatert til søket ditt
- Søk medisinske urter etter deres effekter
- Organiser dine interesser og hold deg oppdatert med nyheter, kliniske studier og patenter
Skriv inn et symptom eller en sykdom og les om urter som kan hjelpe, skriv en urt og se sykdommer og symptomer den brukes mot.
* All informasjon er basert på publisert vitenskapelig forskning
